Pan Cancer T B.V., a pioneering biotech firm based in Rotterdam, the Netherlands, has successfully concluded a Seed Extension round, securing €4.25 million. This investment round includes participation from new investor InnovationQuarter, alongside continued support from existing backers such as Van Herk Ventures, Thuja Capital, Swanbridge Capital, and Erasmus MC O&O Holdings, bringing Pan Cancer T’s total funding to approximately €11 million. Nina Satih from InnovationQuarter will join as a Supervisory Board observer, underscoring the regional support for Pan Cancer T’s innovative approaches.
The infusion of funds from this round will propel Pan Cancer T towards completing crucial preclinical studies for its lead TCR-T cell product, PCT1, aimed at treating solid cancers. Additionally, it will support the advancement of manufacturing activities and the development of early-stage pipeline projects targeting colorectal and ovarian cancers. The company also plans to enhance its intellectual property portfolio and explore new engineering approaches to bolster its therapeutic offerings.
Rachel Abbott, CEO of Pan Cancer T, expressed her enthusiasm: “We are thrilled with the closing of this financing round, which validates our technology’s potential and positions us strongly to progress our lead product towards clinical trials. This milestone not only supports our commitment to patients with triple negative breast cancer but also sets the stage for securing a Series A round in the near future and expanding our strategic partnerships within the biotech and pharmaceutical industries.”
Kees Recourt, Senior Investment Manager at InnovationQuarter, emphasized the significance of this investment: “InnovationQuarter is proud to support Pan Cancer T in developing state-of-the-art cell therapies to combat challenging cancers. This investment not only strengthens the company’s capabilities but also enhances the Life Sciences and Health cluster in Zuid-Holland.”
Editorial Opinion:
Pan Cancer T’s innovative approach to developing T cell therapies marks a significant stride towards addressing the limitations of current cancer treatments. By targeting solid cancers with specific T cell receptors (TCRs), such as ROPN1 for triple negative breast cancer, Pan Cancer T is poised to make a transformative impact in oncology. Their emphasis on enhancing T cell durability within the hostile tumor microenvironment (TME) showcases their commitment to overcoming critical barriers in cancer therapy. As they move closer to clinical trials and expand their therapeutic pipeline, Pan Cancer T is well-positioned to lead advancements in the field, offering new hope to patients and potential collaborations across the healthcare industry.
For further information or corrections, please contact editor@thetimesmag.com.
